A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies

International Journal of Cancer

Volumn 139, Issue 4, 2016, Pages 824-835

  van Beijnum, Judy R ^a   Thijssen, Victor L ^a   Läppchen, Tilman ^b,c   Wong, Tse J ^a   Verel, Iris ^b   Engbersen, Maurits ^a   Schulkens, Iris A ^a   Rossin, Raffaella ^b   Grüll, Holger ^b   Griffioen, Arjan W ^a   Nowak Sliwinska, Patrycja ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

angiogenesis; antibody; galectin 1; imaging; sprouting; therapy

Indexed keywords

GALECTIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7G4; MONOCLONAL ANTIBODY 9G5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY SPECIFICITY; ARTICLE; BREAST ADENOCARCINOMA; CHORIOALLANTOIC MEMBRANE ASSAY; CONTROLLED STUDY; DRUG DESIGN; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; SPROUTING ANGIOGENESIS; TUMOR VASCULARIZATION;

EID: 84976547030     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30131     Document Type: Article

References (55)

1. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76:597–8.
2. Vasta GR, Ahmed H, Odom EW. Structural and functional diversity of lectin repertoires in invertebrates, protochordates and ectothermic vertebrates. Curr Opin Struct Biol 2004;14:617–30.
3. Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012; 946:21–36.
4. Houzelstein D, Gonçalves IR, Fadden AJ, et al. Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 2004;21:1177–87.
5. Ahmad N, Gabius H-J, Sabesan S, Oscarson S, Brewer CF. Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology 2004;14:817–25.
6. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002;1572:232–54.
7. Leppänen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to alpha2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem 2005;280:5549–62.
8. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004;279:4705–12.
9. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006;16:137R–157R.
10. Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29–41.
11. Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochim Biophys Acta Rev Cancer 2015; 1855:235–247.
12. Schulkens IA, Heusschen R, van den Boogaart V, et al. Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer. PLoS One 2014; 9:e107988
13. Punt S, Thijssen VL, Vrolijk J, et al. Galectin-1, −3 and −9 Expression and Clinical Significance in Squamous Cervical Cancer. PLoS One 2015; 10:e0129119
14. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241–51.
15. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012;36:322–35.
16. Laderach DJ, Gentilini LD, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013;73:86–96.
17. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010;70:6216–24.
18. Ito K, Stannard K, Gabutero E, Clark AM, Neo S-Y, Onturk S, Blanchard H, Ralph SJ. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012;31:763–78.
19. Wu M-H, Hong T-M, Cheng H-W, Pan S-H, Liang Y-R, Hong H-C, Chiang W-F, Wong T-Y, Shieh D-B, Shiau A-L, Jin Y-T, Chen Y-L. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 2009;7:311–8.
20. Thijssen VLJL, Postel R, Brandwijk RJMGE, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006;103:15975–80.
21. Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014; 156:744–58.
22. Wu M-H, Hong H-C, Hong T-M, et al. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 2011;17:1306–16.
23. Mathieu V, Le Mercier M, De Neve N, et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 2007;127:2399–410.
24. Dings RPM, Levine JI, Brown SG, et al. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs 2013;31:1142–50.
25. Läppchen T, Dings RPM, Rossin R, et al. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem 2015;89:279–95.
26. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2013;32:363–74.
27. van Beijnum JR, van der Linden E, Griffioen AW. Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res 2008;314:264–72.
28. Fontijn R, Hop C, Brinkman HJ, et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 1995;216:199–207.
29. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21–6.
30. Yang T, Roder KE, Abbruscato TJ. Evaluation of bEnd5 cell line as an in vitro model for the blood-brain barrier under normal and hypoxic/aglycemic conditions. J Pharm Sci 2007;96:3196–213.
31. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978;15:393–403.
32. Sanches PG, Peters S, Rossin R, et al. Bone metastasis imaging with SPECT/CT/MRI: a preclinical toolbox for therapy studies. Bone 2015;75:62–71.
33. Hirabayashi J, Kasai K. Effect of amino acid substitution by sited-directed mutagenesis on the carbohydrate recognition and stability of human 14-kDa beta-galactoside-binding lectin. J Biol Chem 1991;266:23648–53.
34. Sörme P, Kahl-Knutsson B, Huflejt M, et al. Fluorescence polarization as an analytical tool to evaluate galectin–ligand interactions. Anal Biochem 2004;334:36–47.
35. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313–9.
36. Schulkens IAE, Kleibeuker EA, Castricum KCM, et al. Examination of the role of galectins and galectin inhibitors in endothelial cell biology. Methods Mol Biol 2015;1207:285–91.
37. Nowak-Sliwinska P, Segura T, Iruela-Arispe ML. The chicken chorioallantoic membrane model in biology, medicine and bioengineering. Angiogenesis 2014;17:779–804.
38. Nowak-Sliwinska P, Ballini J-P, Wagnières G, et al. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res 2010;79:21–8.
39. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, et al. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010;13:281–92.
40. Burvenich IJG, Lee FT, Cartwright GA, et al. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clin Cancer Res 2013;19:5984–93.
41. Chauhan SC, Jain M, Moore ED, et al. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 2005;32:264–73.
42. Shin IS, Lee S-M, Kim HS, et al. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol 2011;38:1119–27.
43. Lim SH, Nowak-Sliwinska P, Kamarulzaman FA, et al. The neovessel occlusion efficacy of 15-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy. Photochem Photobiol 86:397–402.
44. Freitag N, Tirado-Gonzalez I, Barrientos G, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci 2013;110:11451–6.
45. Ding H, Carlton MM, Povoski SP, et al. Site specific discrete PEGylation of (124)I-labeled mCC49 Fab’ fragments improves tumor MicroPET/CT imaging in mice. Bioconjug Chem 2013;24:1945–54.
46. Diels-Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody. J Nucl Med 2013;54:1989–95.
47. Honjo Y, Inohara H, Akahani S, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000;6:4635–40.
48. Sanjuán X, Fernández PL, Castells A, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997;113:1906–15.
49. Mathieu A, Saal I, Vuckovic A, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 2005;18:1264–71.
50. Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530–41.
51. Wu F, Hu N, Li Y, et al. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol (Dordr) 2012;35:175–80.
52. Balan V, Nangia-Makker P, Schwartz AG, et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 2008;68:10045–50.
53. Wang Y, Nangia-Makker P, Tait L, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009;174:1515–23.
54. Nishioka T, Sakumi K, Miura T, et al. fosB gene products trigger cell proliferation and morphological alteration with an increased expression of a novel processed from of galectin-1 in the Rat 3Y1 embroyo cell line. J Biochem 2002;131:653–61.
55. Gaughan CL. The present state of the art in expression, production and characterization of monoclonal antibodies. Mol Divers 2016;20:255−70.